Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have identified the TAF/FGF5/FGFR2/c-Src/HER2 axis as an escape pathway responsible for HER2 targeted therapies resistance in breast cancer which can be reversed by FGFR inhibitors.
|
31699826 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
|
31841262 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A retrospective series of 686 ER+/HER2- BC were reclassified using AJCC 2018, and in the group of 521 patients for which AJCC 2018 recommends molecular evaluation, we assessed the prognostic efficacy of a prognostic stage enriched by Ki67 (Ki67-PS), considering Ki67 <20% an alternative to recurrence score <11 provided by Oncotype DX.
|
31780778 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Clinical Validation of BCT Scores With Prognostic Factors in Hormone Receptor-positive, HER2-negative Early Breast Cancer.
|
31662548 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, we found that there were 33 gene locus mutations of 8 genes including AKT1, APC, BRAF, CDKN2A, KRAS, PTEN, PIK3CA and TP53, but difference was not statistically significant (P > 0.05) when compared these gene mutations (except for PIK3CA) in each groups according to the histological classification of breast cancer and the ER/PR/HER2 classification.
|
30443844 |
2020 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, by using human epidermal growth factor receptor 2 (<i>HER2</i>) as a model, we quantified individual <i>HER2</i> mRNA molecules in clinical breast cancer FFPE tissue sections and demonstrated its potential to resolve FISH-equivocal cases.
|
31782306 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The HERmione study showed that, in a real-life setting, the safety of SC trastuzumab administered in HER2-positive eBC patients is consistent with data reported from previous clinical trials, without new safety concerns or QoL deterioration.
|
31670262 |
2020 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression of androgen receptor in primary breast carcinoma and its relation with clinicopathologic features, estrogen, progesterone, and her-2 receptor status.
|
31603099 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Compared with non-carriers, PALB2 pathogenic mutation carriers developed breast cancer at a younger age (47.52 years vs. 51.35 years, p = 0.016) and were more likely to have triple-negative (24.1% vs. 13.4%, p = 0.022) or HER2 negative (87.0% vs. 74.2%, p = 0.031) breast cancer and large breast tumors (> 2 cm) at diagnosis (72.2% vs. 57.0%, p = 0.024).
|
31768816 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Breast cancer with microcalcifications was significantly more positive for human epidermal growth factor receptor 2 than those without microcalcifications (48% vs. 22%, P = .018).
|
31255548 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Sensitive and precise detection of ER, PR, and HER2 is of great significance for the diagnosis of breast cancer.
|
31665670 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The potential markers of endocrine resistance among HR+ /HER2+ breast cancer patients.
|
31209793 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results support the classification of HER2+ BC into two major subgroups, LH-high and NLH, based on tumour morphology and immune response; LH-high proliferates via scirrhous and/or spiculated growth with a central scar, while the primary proliferation pattern of NLH is based on in situ carcinomas containing comedo necrosis with noticeable TILs and healing.
|
31554015 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Transferred-tissue Microarray for Fluorescence In Situ Hybridization Test for Human Epidermal Growth Factor Receptor 2 in Breast Cancer.
|
30653031 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
|
31582515 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, TLR3 and TLR9 displayed significantly different expression levels in ER‑/PR‑negative breast cancer compared with the control tissues, while TLR5 expression was significantly reduced in HER2‑enriched breast cancer.
|
31789409 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
EpCAM (epithelial cellular adhesion molecule) and HER2 (human epidermal growth factor receptor 2) are two main circulating tumor cell (CTC) subsets in HER2+ breast cancer patients.
|
31583566 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here, we apply this approach to human epidermal growth factor receptor 2 (HER2)-expressing breast cancer by engineering exosomes through genetic display of both anti-human CD3 and anti-human HER2 antibodies, resulting in SMART-Exos dually targeting T cell CD3 and breast cancer-associated HER2 receptors.
|
31843452 |
2020 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of HO-1 in HER2-expressing SKBR3 breast cancer cells resulted in reduced sensitivity to both pan-HER family kinase inhibitors sapatinib and lapatinib.
|
31705351 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of the present study is to elucidate the anticancer effect of its 6 α-hydroxy-4[14], 10[15]-guainadien-8β, 12-olide (SRCP1) against HER-2 positive subtype of breast carcinoma.
|
31678110 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the role of HER2 and trastuzumab in oxidative stress is not yet completely understood, we suggest that trastuzumab may be a suitable agent for treatment in patients with HER2-enriched breast cancer in a non-oxidative chemotherapy scheme, with acceptable responses and no triggering hemolytic crisis.
|
31260379 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Triple-negative (TN) breast cancer (testing negative for estrogen, progesterone, and Her2 receptors) has elevated GLS protein levels and reportedly depends on exogenous glutamine and GLS activity for survival.
|
31541193 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In 2013, HER2 results were evaluated using two sets of four different breast cancer specimens in five laboratories.
|
31424659 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Many studies have demonstrated that the extracellular domain of human epidermal growth factor receptor 2 (HER2 ECD) level in serum can act as a breast cancer biomarker and serve as a monitoring neoadjuvant therapy of breast cancer.
|
31790576 |
2020 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with backbone endocrine therapy have markedly improved progression-free survival and overall survival over endocrine therapy alone in advanced hormone receptor-positive, HER2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) breast cancer and are the standard of care in the first- or second-line setting.
|
31780379 |
2020 |